Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Maswali ya Kumbukumbu za Baadaye na za Nyuma× | Kiwango cha Tathmini ya Ugonjwa wa Alzheimer-Cognitive× | |
|---|---|---|
| Nyanja | Neurosaikolojia | Neurosaikolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 2003 | 1984 |
| Mwanzilishi≠ | John Crawford | William Rosen |
| Aina≠ | Self-report questionnaire of prospective and retrospective memory complaints | Clinician-administered cognitive scale for Alzheimer's disease |
| Chanzo asilia≠ | Crawford, J. R., Smith, G., Maylor, E. A., Della Sala, S., & Logie, R. H. (2003). The Prospective and Retrospective Memory Questionnaire (PRMQ): Normative data and latent structure in a large non-clinical sample. Memory, 11(3), 261-275. DOI ↗ | Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141(11), 1356-1364. DOI ↗ |
| Majina mbadala≠ | PRMQ, Prospective Retrospective Memory Questionnaire | ADAS-Cog, ADAS-Cog14, ADAS-Cog13 |
| Zinazohusiana | 5 | 5 |
| Muhtasari≠ | The Prospective and Retrospective Memory Questionnaire (PRMQ) is a 16-item self-report instrument designed to measure subjective memory complaints across two distinct memory domains: prospective memory (remembering to do things in the future) and retrospective memory (remembering past events and information). Developed by Crawford and colleagues at the University of Edinburgh in 2003, the PRMQ provides a brief, validated tool for assessing everyday memory lapses and their impact on functional well-being in both clinical and non-clinical populations. | The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is a clinician-administered cognitive assessment instrument designed specifically to measure cognitive decline in Alzheimer's disease. Developed by Rosen, Mohs, and Davis in 1984 and published in the American Journal of Psychiatry, the ADAS-Cog has become the gold standard outcome measure in pharmaceutical trials of antidementia drugs. It is sensitive to disease progression and capable of detecting cognitive change over periods as brief as 6–12 months. |
| ScholarGateSeti ya data ↗ |
|
|